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ABSTRACT
African-American women face a lower risk of being
diagnosed with breast cancer as compared to
Caucasian-American women, yet they paradoxically
face an increased breast cancer mortality hazard. An
increased incidence rate for early-onset disease has
also been documented. This manuscript review sum-
marizes the socioeconomic, environmental, genetic,
and possible primary tumor biologic factors that
may explain these disparities. The Oncologist
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INTRODUCTION
Breast cancer incidence is lower in African-American than
in Caucasian-American women, yet breast cancer mortality
rates are paradoxically higher for African-American women
[1, 2]. These poorly understood disparities have been con-
sistently documented in population-based data from the
Surveillance, Epidemiology, and End Results (SEER) pro-
gram since its inception in 1976 [1, 2]. Another notable fea-
ture regarding ethnicity-related variation in the
epidemiology of breast cancer is that African-American
women face a greater risk for being diagnosed with early-
onset disease. This review summarizes the information
available on the epidemiology of breast cancer in African-
American women, as well the possible socioeconomic,
genetic, and primary tumor biologic factors that account for
these variations.
CLINICAL EPIDEMIOLOGY
As shown in Figure 1, breast cancer incidence is lower for
African-American than for Caucasian-American women, yet
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the SEER program 
population-based data
have documented higher
breast cancer mortality
rates among the African-
American community.
The higher mortality
rates are at least partially
explained by the more
advanced stage distribu-
tion that is seen among
African-American breast cancer patients, and these 
disparities are shown in Table 1 [1, 2].
The prevalence and strength of the established breast can-
cer risk factors among African-American women are not well
documented, but some differences in the significance of vari-
ous factors have been reported [3, 4] in analyses of the Contra-
ceptives and Steroid Hormone (CASH) study. Mayberry and
Stoddard-Wright [3] analyzed standard familial and gyneco-
logic risk factors among breast cancer cases (3,934 Caucasian
Americans, 490 African Americans) and controls (3,901 Cau-
casian Americans, 485 African Americans) from the CASH
study and found that age at first live birth, parity, and surgical
menopause had similar associations with breast cancer risk,
but family history and age at menarche behaved differently as
risk factors. For African Americans, first-degree and second-
degree family history of breast cancer had comparable strengths
as risk factors (odds ratios, 1.61 and 1.71, respectively),
whereas the association in Caucasian Americans was notably
stronger in relation to the pattern of family history (odds ratio,
2.16 for first-degree relatives, and 1.44 for second-degree rela-
tives). Relatively younger ages at menarche have also been
reported for African-American women [5], but the impact of
this finding on breast cancer incidence has not been defined.
An intriguing pattern of breast cancer in African-
American women is seen in the age-incidence curves for the
disease, as demonstrated in Figure 2 [1, 2]. Although breast
cancer risk clearly increases as a function of age, African-
American women under the age of 45 years have a greater
incidence of breast cancer than Caucasian-American women
in this young age range. These rates equalize during the fifth
decade of life, and for women over the age of 50 years, inci-
dence rates for Caucasian Americans surpass those for
African Americans, resulting in an overall higher lifetime
risk for the Caucasian Americans. Although the absolute
values of these population-based incidence rates may not
appear very large in magnitude, this ethnicity-related varia-
tion in age distribution is far more striking in clinical prac-
tice, where 20% of Caucasian-American breast cancer
patients are younger than 50 years of age, compared with
30%–40% of African-American breast cancer patients [6].
It has been reported that the crossover in breast cancer age
incidence between African-American and Caucasian-
American women is a relatively recent phenomenon that
evolved over the 1960s [7]. A sudden shift in age distribution
is difficult to explain, making the accuracy of this observation
dubious. The SEER program is the most well-established and
comprehensive registry of population-based cancer data in the
U.S., and case ascertainment for SEER began in 1974. One
could easily speculate that research regarding the cancer bur-
den among African Americans was inadequately documented
during the first half of the twentieth century.
A plausible and interesting explanation for the younger
age distribution of African-American breast cancer patients
has been proposed by Pathak et al. [8]. Those investigators
correlated the short-term increase in breast cancer risk that
occurs in the postpartum period with premenopausal breast
cancer risk. They hypothesized that the higher prevalence of
early childbearing that is observed among African-
American compared with Caucasian-American women
thereby accounts for the higher incidence of early-onset
breast cancer. Palmer et al. [9] reported supporting data for
this concept in an analysis of The Black Women’s Health
Study. Those investigators demonstrated a dual effect of
pregnancy on breast cancer risk: multiparity increased breast
cancer risk prior to the age of 45 years but was protective
against breast cancer risk after age 45.
Postmenopausal obesity is an established risk factor for
breast cancer [10] because of the higher circulating estrogen
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Figure 1. Breast cancer
incidence and mortality in
African and Caucasian
Americans. 
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levels that result from fatty tissue metabolism of adrenal
gland steroids in the absence of ovarian function. Flegal et
al. [11] analyzed the Third National Health and Nutrition
Examination Survey (NHANES III) and found that more
than half the African-American women over the age of 40
years were obese (body mass index ≥30), and more than
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Table 1. Results of selected studies comparing breast cancer in African-American and Caucasian-American women
Study Dataset Feature Caucasian-Americans African-Americans
Li et al. [82] SEER n 97,999 10,560
Stage (%) I 50.4 35.4
III/IV 11.3 18.9
High-grade tumors (%) 32.1 43.2
Tumor ≥5 cm (%) 8.0 15.0
Node-negative (%) 53.9 42.6
ER-negative (%) 22.0 39.2
PR-negative (%) 31.7 46.6
Mortality hazard (95% CI) 1.0 (ref) 1.5 (1.4–1.6)
Li et al. [81] SEER n 75,978 6,915
Age ≥50 years Stage (%) I 53.2 39.1
III/IV 11.1 19.1
High-grade tumors (%) 29.0 37.6
Tumor ≥5 cm (%) 7.4 14.1
Node-negative (%) 54.3 43.2
ER-negative (%) 15.2 24.1
PR-negative (%) 23.8 30.4
Newman et al. [36] Detroit SEER n 1,378 507
Age <40 years Localized stage (%) 52.1 42.4
Median tumor size (cm) 2.6 3.4
Node-negative (%) 45.7 33.3
ER-negative (%) 44.4 61.9
PR-negative (%) 48.8 59.7
Mean survival (months) 50 45
Shavers et al. [37] SEER n 2,638 724
Age <35 years Stage (%) I 26.7 16.4
III/IV 12.3 16.7
High-grade tumors (%) 43.3 54.8
Median tumor size (cm) 2.5 2.8
Node-negative (%) 44.6 36.5
ER-negative (%) 33.1 34.4
PR-negative (%) 35.4 35.6
Mastectomy (%) 53.2 53.7
5-year disease-specific survival 76.5 66.6
Mortality hazard (95% CI) 1.0 (ref) 1.3 (1.0–1.6)
Elledge et al. [80] San Antonio database n 4,885 1,016
Age >50 yrs (%) 76.1 62.6
P53-positive (%) 50.9 54.9
Tumor ≥5 cm (%) 10.9 27.7
Node-negative (%) 57.9 48.8
ER-negative (%) 22.1 37.9
PR-negative (%) 44.0 59.2
HER2/neu-positive (%) 16.1 13.8
5-year overall survival (%) 75 65
Median survival (months) 166 117
Boyer-Chammard et al. [103] Southern California n 10,937 185
Localized disease (%) 61.4 50.8
Median age (years) 64 52
Mortality hazard 1.0 (ref) 2.32 (1.76–3.07)
Clegg et al. [52] SEER
Age ≥50 years 2-year mammography screening rates (%) 70 67
Abbreviations: CI = confidence interval; ER = estrogen receptor; PR = progesterone receptor
80% were overweight (body mass index ≥25). However, as
noted previously, breast cancer incidence rates are signifi-
cantly lower for African-American women in the post-
menopausal age range. The extent to which dietary fat
contributes to breast cancer incidence among African-
American women is unclear at present. Other NHANES
findings have implicated physical inactivity and inadequate
intake of micronutrients, as well as other dietary compo-
nents, as factors contributing to pre- and postmenopausal
breast cancer risk among African-American women [12].
Breast cancer risk is a function of both environmental/
lifestyle exposures and genetic factors. It is therefore appro-
priate to compare patterns of the disease among African
Americans with data regarding the epidemiology of breast
cancer among native African women. Unfortunately, there
is a paucity of population-based data regarding breast can-
cer incidence and mortality in Africa, a large continent
comprised of many diverse nations. Nonetheless, available
data reveal several provocative parallels between African-
American and native African breast cancer patients.
Overall, breast cancer is a relatively unusual malignancy in
African countries. Several investigators have documented a
younger age distribution and a greater prevalence of high-
grade, estrogen-receptor-negative disease among breast
cancer patients in the Ghanaian and Nigerian populations of
western Africa [13–16], similar to the patterns of breast
cancer reported among African-American women. Western
African populations served as the source for most of the
slave trade to colonial North America, and therefore share
a common ancestry with present-generation African
Americans. These parallels suggest the possible contribution
of founder effects.
MOLECULAR AND GENETIC EPIDEMIOLOGY
Early studies of BRCA mutations suggested that they were
relatively rare among African-American women [17]. Since
that time, however, several BRCA-related breast cancers in
African-American women have been identified [18–22], and
these studies are reviewed comprehensively by Olopade et al.
[23]. Germline mutations in the BRCA genes that are specifi-
cally associated with high-risk (but unrelated) African-
American kindreds have also been identified [18, 21, 23], and
it is possible that additional African-associated founder muta-
tions in other breast cancer susceptibility genes will be identi-
fied in the future. While population-based studies regarding
the prevalence of mutations in breast cancer susceptibility
genes are under way, no definitive data are available at present.
Several reports have demonstrated that African-American
women tend to underutilize genetic counseling services
[24–26], and Matthews et al. [24] have underscored the impor-
tance of tailored outreach/educational strategies in order to
improve the participation rates of African-American women in
genetic counseling programs. Currently available data on
genetic predisposition to breast cancer among African
Americans are inadequate for drawing any conclusions regard-
ing whether ethnicity-specific guidelines are warranted for
identifying members of mutation-carrying kindreds. African-
American families appearing to be at high risk for harboring a
BRCA mutation require complete gene sequencing.
Several investigators have confirmed an association
between circulating levels of sex hormones and breast can-
cer risk [27–31]. Ethnicity-related variation in levels of
endogenous hormones [32, 33] has also been reported, and
this issue warrants further study. Bone density is one surro-
gate marker of estrogen levels, and it has been associated
with a higher breast cancer risk. African-American women
tend to be less susceptible to osteoporosis, and greater
radial bone density has been correlated with breast cancer
risk among African-American women by Nelson et al. [34].
Poola et al. [35] have shown that expression of the beta iso-
form in the estrogen receptor (which may be protective
against abnormal proliferative changes in mammary epithe-
lial tissue) may be disproportionately low in African-
American women. Studies thus far provide opportunities
for speculation, but they fail to offer a clear picture of how
hormone levels might account for the unique epidemiology
of breast cancer in African-American women.
As shown in Table 1, the tumors of African-American
breast cancer patients are significantly more likely to be hor-
mone-receptor negative, aneuploid, and node positive. These
patterns persist even after controlling for stage and age, as
demonstrated in studies by Newman et al. [36] and Shavers et
al. [37]. Furthermore, as biomedical research and genotyping
tools develop further, contemporary studies are identifying
other provocative characteristics that appear to be specific to
African-American breast cancer patients. The results of sev-
eral such studies, examining variations in cytochrome P450
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Figure 2. Age-incidence curves for breast cancer in African-American
and Caucasian-American women. 
polymorphisms, estrogen receptor β, p53, and other markers,
are shown in Table 2. These latter observations require 
validation and expansion before their clinical relevance can
be appropriately defined.
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Table 2. Selected studies of primary tumor biology in African-American breast cancer patients, based on contemporary biomedical and molecular 
epidemiologic analyses
Study Sample size Technology/Analysis Findings
Elledge et al. [80] 4,885 Caucasian-American breast Immunohistochemistry for ER/PR, Tumors of African-American women 
cancer patients HER2/neu, p53; flow cytometry for more likely to be hormone receptor 
1,016 African-American breast S-phase fraction and DNA ploidy status negative, with higher S-phase 
cancer patients fraction
777 Hispanic-American breast 
cancer patients
Shiao et al. [110] 47 Caucasian-American breast PCR single-strand conformational Similar rates of somatic p53 
cancer patients polymorphism analysis and DNA mutations, but specific alterations 
45 African-American breast sequencing varied between African-American 
cancer patients and Caucasian-American patients
Guillemette et al. [111] 200 African-American breast Reverse transcriptase PCR analysis African-American-specific 
cancer patients polymorphisms in UG1A1, 
200 African-American controls a steroid-metabolizing gene
Poola et al. [35] 24 African-American breast Reverse transcriptase PCR to analyze Lower expression of estrogen 
cancer patients estrogen receptor isoforms receptor-β and higher expression 
of estrogen receptor-α exon 5 ∆
isoforms
Mehrotra et al. [112] 44 Caucasian-American breast Methylation-specific PCR to analyze Higher frequency of multiple gene 
cancer patients HIN-2; Twist; cyclin D-2; RASSFIA; methylation in young African-
67 African-American breast in situ hybridization PCR to analyze American women with estrogen 
cancer patients HIN-1 mRNA receptor-negative and progesterone 
receptor-negative tumors
Chen et al. [113] 149 African-American women Computer-assisted measurements of Ethnic differences in breast density 
67 Asian-American women mammographic density in Asian- correlated with ethnic variation in 
226 Caucasian-American women American, African-American, and risk require adjustment for age, body 
Caucasian-American women mass index, and reproductive factors; 
measurements of absolute density 
are more meaningful than proportion 
of dense tissue.
Porter et al. [114] 124 African-American breast Immunohistochemistry for ER/PR, Tumors of African-American women 
cancer patients HER2/neu, Ki67, p53, cyclin E, more likely to be higher grade, and 
397 Caucasian-American breast cyclin D1, p27, p16, pRb, and p21 associated with higher mitotic index, 
cancer patients ER/PR negativity, overexpression of 
cyclin E, p16, and p53, and low expre-
ssion of cyclin D1 compared with 
tumors of Caucasian-American women
Millikan et al. [115] 760 African-American breast Genotyping for manganese superoxide Similar predictive value of polymor-
cancer patients dismutase Ala-9Val polymorphism phism among African-American and 
1,265 Caucasian-American breast Caucasian-American breast cancer 
cancer patients patients; polymorphism only associ-
ated with breast cancer in cases with 
smoking history, chest wall XRT, 
and occupational radiation exposure
Li et al. [116] 271 African-American breast Genotyping for cytochrome P450 1A1 Particular CYP 1A1 polymorphisms 
cancer patients; 285 controls (CYP1A1) polymorphisms associated with higher breast 
417 Caucasian-American breast cancer risk among smokers
cancer patients; 417 controls
Jones [117] 177 Caucasian-American breast Immunohistochemistry for c-met, p53 Greater prevalence of p53 alter-
cancer patients ations among African-American 
145 African-American breast women
cancer patients
Abbreviations: ER = estrogen receptor; PR = progesterone receptor; PCR = polymerase chain reaction; XRT = radiation therapy
RISK ASSESSMENT AND CHEMOPREVENTION
Risk assessment research has assumed an increased level of
importance in light of the confirmed efficacy of tamoxifen
[38], prophylactic mastectomy [39], and prophylactic
oophorectomy [40] in reducing breast cancer incidence
among high-risk women. The potential adverse events asso-
ciated with all these risk-reducing strategies mandate the
accurate identification of high-risk women for whom accept-
ing the intervention-related hazards would be worthwhile.
Use of the selective estrogen-receptor modulator
tamoxifen for chemoprevention is particularly relevant to a
discussion of African Americans and breast cancer.
Tamoxifen only reduces the risk of estrogen receptor-posi-
tive tumors, and African-American women have a rela-
tively lower risk for being diagnosed with these favorable
lesions. Furthermore, tamoxifen can cause thromboembolic
phenomena, and morbidity from deep vein thrombosis/pul-
monary emboli is relatively high among African-American
women. On the other hand, tamoxifen-associated adverse
events are uncommon among young women, and pre-
menopausal African-American women face a higher risk
for developing breast cancer. Unfortunately, only 1.7% of
the National Surgical Adjuvant Breast Project (NSABP)-
P01 participants were African American [38], and we there-
fore have no data on efficacy of tamoxifen for pure
chemoprevention in this population subset.
Freedman et al. [41] analyzed breast cancer risk factor
data compiled by the year 2000 National Health Interview
Survey Cancer Control Module in conjunction with the Gail
tamoxifen benefit/risk index [42] to estimate the proportion
of adult women in the U.S. who could benefit from tamox-
ifen therapy. For Caucasian-American women, 15.5%
would be eligible on the basis of risk estimates alone and
4.9% would have a favorable benefit/risk index. For
African-American women, these rates were notably smaller
in magnitude: 5.7% estimated to be risk eligible and 0.6%
estimated to have a favorable benefit/risk index. The rela-
tively low estimates for African-American women are dis-
appointing in light of their known disproportionately
elevated risk for breast cancer mortality. It should be noted,
however, that the benefit/risk analysis accounts for a pre-
sumed greater risk for thromboembolism and stroke among
African-American women (based on extrapolations from
mortality data), but ethnicity-related differences in breast
cancer mortality are not weighted into the index.
The incomplete understanding of risk factor exposures in
African-American women has resulted in doubts regarding
our ability to accurately predict breast cancer risk in this pop-
ulation subset via the established tools utilized for
Caucasian-American women. The Gail breast cancer risk
assessment model [43] allows for estimation of individualized
likelihood of developing breast cancer. This model is a logis-
tic regression equation based on risk factor data from partic-
ipants of the Breast Cancer Detection and Demonstration
Project, a mammography screening program conducted by
the American Cancer Society during the 1970s. Very few
African-American women participated in this program, and
the model was, therefore, limited to risk factor exposure data
from a case-control subset of the Caucasian participants, and
in its original formulation it was appropriately labeled as a
model to predict breast cancer risk in Caucasian-American
women receiving annual mammographic screening. Risk
estimates computed by this model are the primary means of
determining eligibility for the NSABP chemoprevention 
trials, and so the model has been modified to adjust for risk 
calculations in African-American women as well.
The Gail model quantifies breast cancer risk by multi-
plying the relative risks for four different factors by the wom-
an’s age-specific baseline hazard for developing breast
cancer. The model risk factors are age at menarche, age at
first live birth, number of first-degree relatives with breast
cancer, and number of breast biopsies. The age-specific base-
line risk represents the absolute likelihood that a woman will
develop breast cancer in the absence of increased risk con-
ferred by the four model risk factors; this baseline is derived
from SEER program age- and ethnicity-specific breast can-
cer incidence rates. The SEER program provides breast can-
cer incidence for the general population of women and a
composite of various risk factor expressions. An approxima-
tion of the true baseline risk is extrapolated from these com-
posite-risk incidence rates by subtracting the amount of
disease that is estimated to have resulted from risk conferred
by the four model risk factors (population attributable risk).
Population attributable risk estimates are typically calculated
from known data on risk factor prevalence rates.
The validity of the Gail model in accurately identifying
groups of high-risk patients was demonstrated in three dif-
ferent populations of Caucasian-American women [44–47].
Recently, the model was evaluated in African-American
women based on case-control data from the Women’s
Contraceptive and Reproductive Experiences study. This
analysis suggested that the model tends to underestimate risk
for African-American women and generated questions
regarding accuracy of the baseline risk estimate component
of the model, especially for the subset of young African-
American women [48, 49]. Utilization of a revised model
with adjusted baseline risk estimates has been proposed.
EARLY DETECTION AND SCREENING
The relatively more advanced stage distribution of breast
cancer motivates the concern that African-American women
receive suboptimal breast cancer surveillance. Widespread
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adoption of annual mammography screening practices since
the 1970s among American women over the age of 40 years
is credited for the recent improvements observed in popula-
tion-based breast cancer outcome, as a direct consequence of
increasing the proportion of screen-detected early-stage
tumors [50]. SEER data reveal that between 1983 and 1998,
the proportions of in situ and stage I disease doubled for the
entire population [1]. As noted previously, however, African-
American women continue to present with greater propor-
tions of advanced-stage disease, despite recent data indicating
increases in mammography utilization among African-
American women that are comparable with utilization rates
among Caucasian-American women, approaching 70% [51].
Hence, the impact of screening patterns and follow-up in
African-American women is incompletely understood.
The National Health Interview Survey (NHIS) utilizes
specially trained U.S. Census Bureau personnel to collect
health status and health care information on representative
segments of the American population via personal house-
hold interviews conducted continuously since 1975. NHIS
data reveal significant increases in utilization of mammo-
graphy screening for both African Americans and Caucasian
Americans since 1987. For women over 40 years of age,
approximately one-quarter of both groups reported having
had a mammogram within the past 2 years in 1987. In 2000,
these rates increased to 71.4% for Caucasian Americans and
67.8% for African-American women. Interestingly, the dis-
parity in mammography utilization is larger for women aged
40–49 years, where the rates are 67.1% for Caucasian and
60.9% for African Americans [51–53].
The younger age distribution for breast cancer among
African-American women leads to concerns regarding the
efficacy of screening mammography, an imaging modality
with limited accuracy in young women. This issue is not
addressed in any of the original mammography screening
trials because few African-American women were included
in those phase III studies [54]. The international trials, by
definition, would not have been expected to sample African-
American women, and the Health Initiatives Program of
New York screening trial included fewer than 6% African-
American participants. The paucity of data regarding sur-
veillance mammography in African-Americans is reviewed
by Royak-Schaler and Rose [55]. Jones et al. [56] reported
that history of mammographic screening accounted for less
than 10% of the higher risk for advanced-stage disease
observed in a population-based study of breast cancer in
African-American compared with Caucasian-American
women from Connecticut. In contrast, McCarthy et al. [57]
linked Medicare records on mammography claims with
SEER data and found that history of mammography use
accounted for 30% of the stage distribution disparity between
older-aged African-American and Caucasian-American
women. Patterson et al. [58] reported similar mammographic
appearance for breast cancers detected in African-American
compared with Caucasian-American women.
EFFECT OF SOCIOECONOMIC STATUS (SES)
In 1989, Freeman and Wasfie documented the powerful
effects of African-American ethnicity combined with
poverty on breast cancer outcome based on data from the
Harlem Hospital Center [59]. That study reported a 39% 5-
year survival rate for 512 surgically treated breast cancer
patients between 1964 and 1986. Ninety-four percent of
those patients were African American and only 6% presented
with stage I disease, suggesting that few women in that sys-
tem were undergoing mammographic screening for breast
cancer. The Breast Examination Center of Harlem was estab-
lished to address this health care deficit, and recently pub-
lished findings [60] from that center demonstrate dramatic
improvements in breast cancer stage distribution for the
Harlem population. Between 1995 and 2000, nearly half the
breast cancers detected were stage 0 or I disease.
Successful outreach and surveillance programs such as
these suggest that ethnicity-related disparities in breast can-
cer survival can be reduced substantially by optimizing
early detection with mammographic screening. However,
national data have revealed a narrowing in the magnitude of
difference for mammography utilization rates for African-
American compared with Caucasian-American women, and
yet differences in stage distribution persist. It might, there-
fore, be inferred that outcome disparities will not be elimi-
nated entirely by intensive screening efforts alone.
Socioeconomic factors probably account for a substan-
tial proportion of breast cancer outcome disparities. As
shown in Figure 3, poverty rates, likelihood of lacking med-
ical insurance, and likelihood of relying on public insurance
such as Medicaid are twice as high for African Americans
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Figure 3. Proportions of African Americans compared with
Caucasian Americans living below the poverty level, covered by
Medicaid insurance, or completely uninsured [102].
compared with Caucasian Americans. These economic bar-
riers to health care access certainly contribute to delays in
breast cancer diagnosis and treatment, ultimately resulting
in higher mortality rates.
Several studies have attempted to account for SES in
evaluating ethnicity-related variation in breast cancer out-
come. Findings from fourteen studies [61–74] published over
the past 20 years were analyzed in a meta-analysis reported
by Newman et al. [75]. Several patterns were apparent on
careful scrutiny of these studies. First, socioeconomic disad-
vantages are more prevalent among African-American com-
pared with Caucasian-American patients, as expected.
Secondly, crude survival analyses demonstrate worse out-
comes for the African-American breast cancer patients, which
correlates with national population-based data from the SEER
program. A third and final pattern is that adjustments to the
survival analyses based on SES generally result in diminu-
tion or complete elimination of any statistically significant
association with ethnicity. A necessary corollary to the
adjusted survival comparisons is a reduction in the statistical
power to evaluate ethnicity and SES, since the resulting com-
parison involves a relatively smaller subset of affluent African-
American breast cancer patients and a relatively larger subset
of affluent Caucasian-American breast cancer patients. The
pooled data yielded a more robust sample size, with more than
10,000 African-American and 40,000 Caucasian-American
breast cancer patients contributing to the analysis. After
adjusting for SES, stage, and age at diagnosis, a 22% higher
mortality risk was seen among the African-American patients
(mortality odds ratio, 1.22; 95% confidence interval: 1.13-
1.30). The individual studies included in this meta-analysis
evaluated other markers of tumor biology to varying degrees.
Some studies included tumor grade, some included hormone
receptor status, and others included histology in their
adjusted, proportional hazards survival analyses. The sum-
mary data from the pooled analysis are shown in Figure 4.
Bradley et al. [76] published a recent report that under-
scores the complexities of SES and breast cancer survival
analyses. Those investigators utilized Medicaid and census
tract data linked to the Metropolitan Detroit SEER registry.
African-American background was a predictor of worse
outcome on univariate analysis; however, in the multivari-
ate analysis that adjusted for residence in a high-poverty
neighborhood (at least 5% of households below the poverty
level), Medicaid coverage, stage, age, marital status, treat-
ment, and disease stage retained the strongest significance
levels independently. Notably, more than half the entire
study population was categorized as residing in a low-
income neighborhood, and only 19% of the study population
was African American. The sample size of African-
American breast cancer patients who were coded as not
being poor was probably very small, and this study was
therefore left with neither ethnicity nor SES retaining statis-
tical significance. The authors nonetheless concluded that
SES was probably the major determinant of poor outcome
by leading to advanced stage at diagnosis.
As discussed in the meta-analysis, measures of SES are
inconsistent and poorly validated. Furthermore, the prognos-
tic value of SES is easily confounded by diet, lifestyle, and
cultural factors, all of which may have ethnicity-based varia-
tions. Barriers to health care access secondary to poverty
clearly exert a negative influence on breast cancer outcome.
Quantifying the independent effects of SES, ethnicity, hered-
itary factors, and lifestyle/environmental exposures on breast
tumor biology is therefore a formidable challenge.
TREATMENT EFFECTS
Ethnicity-related variation in breast cancer treatment could
influence outcome as a consequence of either A) inherent
resistance to therapy related to primary disease factors or B)
inequalities in delivery of care. There is heterogeneity in
breast tumor biology as well as in health care environments,
and the individual breast cancer patient might therefore be
impacted by either, both, or neither of these factors.
Locoregional recurrence rates tend to be higher in
younger breast cancer patients treated by lumpectomy. The
younger age distribution of African-American breast cancer
patients therefore warrants a closer look at outcome follow-
ing breast conservation therapy (BCT). Several studies
(Table 3) have, therefore, evaluated BCT in African-
American and Caucasian-American breast cancer patients.
As reviewed by Newman et al. [77], overall BCT utilization
rates are relatively low for both patient populations, and
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Figure 4. Meta-analysis of studies comparing outcome from breast
cancer in African-American (n = 10,001) and Caucasian-American 
(n = 42,473) patients, after adjusting for age, stage, and SES.
Mortality odds ratio 1.22; 95% confidence interval 1.13-1.30.
*Patients <50 years of age. **Patients ≥50 years of age [75].
10510.50.1
Mortality odds ratio
Combined
Roetzheim
ElTamer
Yood
Wojcik
Howard
Franzini
Simon**
Simon*
Perkins
Eley
Neale
Ansell
Gordon
Coates
Bassett
although some data indicate a higher risk of local recurrence
for African-American women, this may be related to underly-
ing tumor biology, as the risk of local recurrence is greater
following mastectomy as well [78]. Some interesting patterns
of locoregional and distant failure following BCT were
reported by Pierce et al. [79] in a study of BCT in 75 African-
American and 615 Caucasian-American breast cancer
patients. Local-only recurrence was similarly low for both
subsets of patients (5% and 6%, respectively), but the risks of
regional failure (especially in the supraclavicular nodal basin)
and distant metastases were significantly higher for the
African-American patients.
As noted previously, African-American breast cancer
patients are more likely to have estrogen receptor-negative
disease [36, 37, 80–82]. This variation clearly influences
cancer management, as endocrine therapy is contraindi-
cated and replaced by chemotherapy as the only option for
adjuvant systemic treatment for these estrogen receptor-
negative tumors. For African-American patients with estro-
gen receptor-positive tumors, however, hormonal therapy
with tamoxifen appears to have equivalent efficacy to when
delivered to Caucasian-American breast cancer patients, as
demonstrated by McCaskill-Stevens et al. [83] in a pooled
analysis of NSABP adjuvant therapy studies. Nonetheless,
population-based data on comorbidities raise some interest-
ing questions with regard to selection of endocrine therapy.
As noted previously, thromboembolism is relatively more
prevalent among African Americans and is also a known
potential complication of tamoxifen therapy. Aromatase
inhibitors have a lower risk of exacerbating thromboem-
bolic problems but pose a risk of accelerated osteoporosis
[84]. African-American women tend to have a lower risk of
osteoporotic bones than Caucasian-American women. One
might, therefore, postulate that aromatase inhibitors would
be the preferred hormonal therapy for postmenopausal
African-American women diagnosed with estrogen recep-
tor-positive breast cancer. Unfortunately, there are no pub-
lished data on efficacy and side effects of aromatase
inhibitors in African-American women.
Chemosensitivity of breast cancer in African Americans
has been studied indirectly. Growing work in the area of
pharmacogenetics is resulting in the identification of various
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Table 3. Selected studies of breast conservation therapy in African-American women
n of patients
African
Study American Caucasian Study criteria Median follow-up Findings
Burri et al. [104] 72 29 All BCT cases; mostly Estimated Local control for African-American patients 
indigent population 5 years 95.2% at 5 years; 87.9% at 10 years;
Disease-free survival rate for African-American 
patients 84.6% at 5 years; 65.3% at 10 years.
Connor et al. [105] 71 204 Stage I/II; all treated 53 months Trend for higher local recurrence rate in 
with BCT African Americans (n.s.)
Nicolaou et al. [106] 41 301 Stage IIA/B; node 73 months Higher regional relapse rate among African 
positive; all treated Americans (19% versus 1%; p < 0.0001)
with BCT
Velanovich et al. [107] 416 834 Stages I-IV; treatment NA Similar rates of BCT among African-American 
variable and Caucasian-American patients (54.5% 
versus 57.2%)
Newman et al. [78] 211 NA T1/T2 tumors; 68 months BCT rate 19.9%
treatment variable Similar local recurrence and survival rates 
in BCT and mastectomy patients (9.8% 
versus 8.9%)
Arnold et al. [108] 107 131 All treated in an urban NA BCT rate 36% for African-Americans; 41% 
teaching hospital for Caucasian-American patients 
Muss et al. [109] 160 145 Stage II; node positive; NA Lower BCT rates among African-American 
treatment variable than among Caucasian-Americans patients 
(22% versus 40%; p = 0.004)
Pierce et al. [79] 75 615 Stage I/II; all treated 56 months Similar local recurrence rates for African-
with BCT American and Caucasian-Americans patients 
(5% versus 6%); higher regional relapse rates 
for African-American patients (16% versus 
4%; p = 0.001)
Abbreviation: n.s. = not significant
polymorphisms in proteins that are involved with metabo-
lism of cancer-treating therapies. Polymorphisms in cyto-
chrome P450/CYP enzymes are known to have variable
prevalence rates among different ethnically defined subsets
of the population [85, 86] and could potentially alter
chemotherapy effectiveness. Review of the MD Anderson
locally advanced breast cancer database, however, revealed
similar clinical and pathologic response rates to induction
chemotherapy for African-American and Caucasian-
American breast cancer patients [87].
A provocative study, reported by Hershman et al. [88],
demonstrated that African-American breast cancer patients
were more likely to experience delays in completion of
adjuvant chemotherapy regimens related to neutropenia,
and that this prolongation of treatment may correlate with a
lower overall dose intensity. Interestingly, the clinical rele-
vance of ethnicity-related neutropenia is poorly understood,
as baseline neutrophil counts were lower among the
African-American patients, and this hematologic pattern
has been noted among the general population as well. The
potential confounding effect of obesity rates among
African-American breast cancer patients and its impact on
chemotherapy dosing also requires further study.
Unfortunately, disparities in delivery of treatment to
African-American breast cancer patients have also been
reported [89], raising the concern that discriminatory prac-
tices in the health care system may also contribute to out-
come disparities. These disparities may be unintentional
and related to miscommunication between patient and
health care provider or they may be related to socioeco-
nomic issues. Chu et al. [90] reported that the magnitude of
difference in breast cancer outcome between African-
American and Caucasian-American patients was mini-
mized among women age 65 or older, and the authors
interpreted their findings as implying that more effective
breast cancer treatment was delivered to women who were
more likely to have health care coverage by virtue of being
age eligible for Medicare benefits. Breen et al. [89] found evi-
dence of unequal breast cancer management in a subset analy-
sis conducted on participants of the Black/White Cancer
Survival Study, where 21% of African-American patients
failed to receive the minimum expected standard of care 
(as defined by National Cancer Institute consensus state-
ments), compared with 15% of Caucasian-American patients.
Standardization of care through the clinical trials mecha-
nism would be expected to abolish the influence of ethnicity-
related treatment and/or socioeconomic disparities on breast
cancer outcome, thereby providing a “pure” assessment of
ethnicity-related survival. Roach et al. [91] examined breast
cancer survival among African-American and Caucasian-
American participants of a Cancer and Leukemia Group B
phase III study of node-positive disease and found a worse
outcome for the African Americans in a univariate analysis.
The investigators were able to eliminate the statistical sig-
nificance of this association by performing a multivariate
logistic regression analysis that included age, hormone-
receptor expression, number of metastatic nodes, and
chemotherapy dose. This latter analysis was clearly
affected by progressive loss of statistical power related to
small subset sample sizes.
Subset analyses of NSABP trials have yielded inconsis-
tent results regarding the influence of ethnic background on
outcome. An early analysis of outcome predictors for the
NSABP B-06 trial revealed worse survival for African-
American participants [92]. In contrast, more recent reviews
of the NSABP protocols reported by Dignam [93, 94]
revealed that, after accounting for other primary tumor fea-
tures, African-American ethnicity was generally not an inde-
pendent predictor of worse disease-free outcome. Overall
mortality rates, however, were significantly higher for
African Americans, suggesting that comorbidities may be
exerting an effect.
Albain et al. [95] conducted one of the most recent and
powerful studies presented to date on the issue of ethnicity-
related breast cancer outcome within the context of the clin-
ical trials setting. The Southwest Oncology Group pooled
the data on all breast cancer patients (nearly 7,000 cases)
participating in five prospective, randomized, adjuvant
therapy clinical trials conducted between 1975 and 1995.
Albain et al. analyzed survival for these studies (consisting
of approximately 10% African-American patients) after
adjusting for SES, age, and disease stage. They found that
African-American ethnicity was a statistically significant
and independent predictor of mortality risk in the multi-
variate survival analyses of both pre- and postmenopausal
breast cancer patients. Hazard ratios for mortality in the
overall survival analysis were 1.41 (95% confidence inter-
val, 1.10–1.82) for premenopausal African-American
women and 1.49 (95% confidence interval, 1.28–1.73) for
postmenopausal African-American women. Similar statisti-
cally significant outcome disadvantages were reported for
disease-free survival.
FUTURE DIRECTIONS
As biomedical technology and techniques of molecular epi-
demiology continue to mature, we are likely to gain
improved insight regarding modifiable versus fixed deter-
minants of breast cancer risk as well as treatment response.
However, it will be incumbent upon the oncology research
community to design studies that account for ethnic ances-
try to the greatest extent possible, so that ethnicity-related
variations can be defined. The health care provider 
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community must assume responsibility for implementing
outreach programs that optimize African-American partici-
pation in genetic counseling programs, breast cancer
screening programs, and treatment, as well as chemopre-
vention clinical trials. These efforts will strengthen the like-
lihood of successful research endeavors. The importance of
survivor advocates, social networks, and church-based sup-
port groups appears to be quite valuable in achieving the
outreach goals [96–100]. In particular, cancer care
providers should be aware of the Sisters Network, Inc., a
national African-American survivor advocate organization
that has provided breast health awareness information and
clinical trials support to thousands of women in the
African-American community since its inception in 1994
[101]. Information regarding the support services and
resources offered by this organization is available at their
website, www.sistersnetwork.com.
SUMMARY
Breast cancer pathogenesis and epidemiology are complex and
influenced by the myriad of environmental and lifestyle factors
that impact on lifetime hormone exposures. The genetic,
socioeconomic, and cultural features associated with ethnic
background complicate the picture further. For African-
American women these various elements converge to yield the
paradoxical patterns of a relatively lower breast cancer inci-
dence, higher mortality rate, and younger age distribution.
Expanded breast cancer screening programs and attention to
assuring equality in delivery of care should result in some
degree of improved outcome. It is also essential to ensure
increased accrual of African Americans into chemoprevention
as well as treatment trials. As microarray technology to evalu-
ate the genetic composition of tumors becomes more widely
available, many of the questions regarding ethnicity-associated
variation in primary cancer biology will be clarified.
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